全文获取类型
收费全文 | 378804篇 |
免费 | 27695篇 |
国内免费 | 13600篇 |
专业分类
耳鼻咽喉 | 5181篇 |
儿科学 | 11709篇 |
妇产科学 | 4933篇 |
基础医学 | 45366篇 |
口腔科学 | 9524篇 |
临床医学 | 38570篇 |
内科学 | 60092篇 |
皮肤病学 | 7216篇 |
神经病学 | 19450篇 |
特种医学 | 15857篇 |
外国民族医学 | 136篇 |
外科学 | 48201篇 |
综合类 | 45385篇 |
现状与发展 | 68篇 |
预防医学 | 18626篇 |
眼科学 | 7754篇 |
药学 | 35113篇 |
104篇 | |
中国医学 | 9348篇 |
肿瘤学 | 37466篇 |
出版年
2023年 | 4087篇 |
2022年 | 6447篇 |
2021年 | 13843篇 |
2020年 | 10353篇 |
2019年 | 15881篇 |
2018年 | 10964篇 |
2017年 | 10455篇 |
2016年 | 12667篇 |
2015年 | 16215篇 |
2014年 | 26905篇 |
2013年 | 25777篇 |
2012年 | 27625篇 |
2011年 | 25599篇 |
2010年 | 22712篇 |
2009年 | 22068篇 |
2008年 | 21110篇 |
2007年 | 21375篇 |
2006年 | 18721篇 |
2005年 | 14536篇 |
2004年 | 10324篇 |
2003年 | 9064篇 |
2002年 | 7377篇 |
2001年 | 6298篇 |
2000年 | 5328篇 |
1999年 | 4184篇 |
1998年 | 3987篇 |
1997年 | 3816篇 |
1996年 | 3279篇 |
1995年 | 3346篇 |
1994年 | 3046篇 |
1993年 | 2435篇 |
1992年 | 2347篇 |
1991年 | 2157篇 |
1990年 | 1936篇 |
1989年 | 1863篇 |
1988年 | 1737篇 |
1987年 | 1458篇 |
1986年 | 1264篇 |
1985年 | 2363篇 |
1984年 | 2395篇 |
1983年 | 1738篇 |
1982年 | 1836篇 |
1981年 | 1717篇 |
1980年 | 1495篇 |
1979年 | 1254篇 |
1978年 | 935篇 |
1977年 | 892篇 |
1976年 | 762篇 |
1974年 | 483篇 |
1973年 | 469篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Association of Multimodal Pain Control with Patient-Reported Outcomes in Children Undergoing Surgery
《Journal of pediatric surgery》2023,58(6):1206-1212
IntroductionOur aim was to describe practices in multimodal pain management at US children's hospitals and evaluate the association between non-opioid pain management strategies and pediatric patient-reported outcomes (PROs).MethodsData were collected as part of the 18-hospital ENhanced Recovery In CHildren Undergoing Surgery (ENRICH-US) clinical trial. Non-opioid pain management strategies included use of preoperative and postoperative non-opioid analgesics, regional anesthetic blocks, and a biobehavioral intervention. PROs included perioperative nervousness, pain-related functional disability, health-related quality of life (HRQoL). Associations were analyzed using multinomial logistic regression models.ResultsAmong 186 patients, 62 (33%) received preoperative analgesics, 186 (100%) postoperative analgesics, 81 (44%) regional anesthetic block, and 135 (73%) used a biobehavioral intervention. Patients were less likely to report worsened as compared to stable nervousness following regional anesthetic block (relative risk ratio [RRR]:0.31, 95% confidence interval [CI]:0.11–0.85), use of a biobehavioral technique (RRR:0.26, 95% CI:0.10–0.70), and both in combination (RRR:0.08, 95% CI:0.02–0.34). There were no associations of non-opioid pain control modalities with pain-related functional disability or HRQoL.ConclusionUse of postoperative non-opioid analgesics have been largely adopted, while preoperative non-opioid analgesics and regional anesthetic blocks are used less frequently. Regional anesthetic blocks and biobehavioral interventions may mitigate postoperative nervousness in children.Level of evidenceIII. 相似文献
2.
认知障碍是指记忆、语言、理解和判断等一个或多个方面的功能障碍,包括轻度认知障碍和各种类型的痴呆症。痴呆症是认知障碍最严重的表现,是一种导致患者日常生活、社会交往和工作能力发生显著变化的综合征。阿尔茨海默病(AD)是最常见的痴呆症类型,其次是血管性痴呆(VD)和其他神经退行性痴呆[1]。已知年龄与认知功能的退化密切相关。 相似文献
3.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
4.
5.
6.
目的探讨肺癌患者化疗后的癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和鳞状上皮细胞癌抗原(SCC-Ag)表达变化。方法选取2017年5月至2020年2月间南京市六合区人民医院收治的100例肺癌患者,将这些患者作为肺癌组,另随机选取同期100例健康体检人员作为健康组。统计分析两组人员化疗前的血清NSE、CEA、SCC-Ag表达水平、肺癌组化疗成功患者化疗前后的血清NSE、CEA、SCC-Ag表达水平、肺癌组化疗失败患者化疗前后的血清NSE、CEA、SCC-Ag表达水平。结果肺癌组患者化疗前的血清NSE、CEA和SCC-Ag表达水平均高于健康组,差异均有统计学意义(均P <0.05)。肺癌组化疗成功患者化疗后的血清NSE、CEA和SCC-Ag表达水平均低于化疗前,均高于健康组,差异均有统计学意义(P <0.05)。肺癌组化疗失败患者化疗后的血清NSE、CEA、SCC-Ag表达水平均高于化疗前,均高于健康组,差异均有统计学意义(P <0.05)。结论对肺癌患者的NSE、CEA、SCC-Ag表达水平进行检测能够将化疗效果有效反映出来,进而有效指导临床的下一步治疗工作,从而有效改善患者预后。 相似文献
7.
Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit 下载免费PDF全文
Sharareh SeifiBabak SalimiZahra Esfahani-MonfaredRamin RadmaneshSaeed YaghoubifardSara TalebianpourAdnan Khosravi 《Asian Pacific journal of cancer prevention》2022,23(4):1155-1158
Background: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). Methods: Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients. Patients with EGFR mutation received Erlova at 150 mg/day as first line treatment. Primary endpoint was progression free survival (PFS). Results: About 21% (n=109) cases had EGFR mutation. Most EGFR mutations were occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about 88%. Most frequent treatment related adverse events was skin rash. Conclusion: Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors. 相似文献
8.
9.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
10.
Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder. 相似文献